Literature DB >> 2477336

A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes.

J Burchell1, J Taylor-Papadimitriou, M Boshell, S Gendler, T Duhig.   

Abstract

The polymorphic epithelial mucin (PEM) appears to be the target molecule for many monoclonal antibodies (MAbs) which react with tumour-associated and epithelium-specific antigens. PEM contains a large domain made up of 20 amino-acid tandem repeats which are highly immunodominant as many of the antibodies reactive with this molecule recognize epitopes within this area. Using overlapping peptide octamers, we have precisely mapped the epitopes of 4 MAbs reactive with the tandem repeats including one, SM-3, which shows enhanced tumour specificity. We report that the core of the SM-3 epitope corresponds to the continuous amino acid sequence Pro-Asp-Thr-Arg-Pro. We also show that the epitopes recognized by 3 other antibodies, which show reactivity with normal and malignant tissues, map to within this area of the tandem repeat. However, none of these epitopes contain the proline found at the amino end of the SM-3 determinant. These results are consistent with the idea that, in the cancer-associated mucin, premature termination of the carbohydrate side-chains results in the exposure of the SM-3 epitope.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477336     DOI: 10.1002/ijc.2910440423

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  37 in total

1.  Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine.

Authors:  P Laing; P Tighe; E Kwiatkowski; J Milligan; M Price; H Sewell
Journal:  Clin Mol Pathol       Date:  1995-06

2.  Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

Authors:  P X Xing; K Reynolds; G A Pietersz; I F McKenzie
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

3.  Results of the central data analysis.

Authors:  P C Beverley; Y Olabiran; J A Ledermann; L G Bobrow; R L Souhami
Journal:  Br J Cancer Suppl       Date:  1991-06

4.  Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice.

Authors:  M Smith; J M Burchell; R Graham; E P Cohen; J Taylor-Papadimitriou
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

Review 5.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

Review 6.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

7.  Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

Authors:  Nehad M Alajez; Jan Schmielau; Mark D Alter; Michael Cascio; Olivera J Finn
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

8.  Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors.

Authors:  Sampat Ingale; Margreet A Wolfert; Therese Buskas; Geert-Jan Boons
Journal:  Chembiochem       Date:  2009-02-13       Impact factor: 3.164

9.  Epitope expression on the breast epithelial mucin.

Authors:  R L Ceriani; J A Peterson; E W Blank; D T Lamport
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

10.  Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer.

Authors:  M Granowska; K E Britton; S J Mather; D G Lowe; D Ellison; J Bomanji; J Burchell; J Taylor-Papadimitriou; C R Hudson; J H Shepherd
Journal:  Eur J Nucl Med       Date:  1993-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.